Table 3. Correlation between SNPs and PFS by treatment arm.

	Placebo			Bevacizumab 7.5 mg kg−1				Bevacizumab 15 mg kg−1
SNP	Events/n	Allelic HRa	AllelicP-valueb	Events/n	Allelic HRa	AllelicP-valueb	Interaction P-value	Events/n	Allelic HRa	AllelicP-valueb	Interaction P-value
VEGF: c.+405/c.-634	89/103	1.503	0.027	98/115	0.934	0.647	0.046	91/109	0.994	0.972	0.087
VEGF: c.+936 C>T	89/103	0.937	0.763	99/116	1.026	0.902	0.813	91/109	1.472	0.039	0.128
VEGF: c.-1154 A>G	89/104	1.091	0.618	99/117	1.443	0.015	0.175	89/109	0.996	0.981	0.767
VEGF: c.-2578 C>A	88/102	0.727	0.043	99/116	1.184	0.237	0.018	91/109	0.924	0.605	0.229
VEGF: c.-460T>C; c.-1498T>C	89/104	0.750	0.066	99/118	1.190	0.213	0.024	88/108	0.925	0.624	0.312
VEGFR-1: rs9554316	88/102	0.992	0.965	99/115	0.945	0.771	0.835	91/109	1.072	0.687	0.774
VEGFR-1: rs9582036	89/103	0.952	0.764	99/116	0.953	0.752	0.980	91/109	1.104	0.552	0.565

Abbreviations: HR=hazard ratio; PFS=progression-free survival; SNP=single-nucleotide polymorphism; VEGF=vascular endothelial growth factor; VEGFR-1=vascular endothelial growth factor receptor 1.

^aHazard ratio between SNPs within the treatment arm.

^bComparison within the treatment arm. Values in bold represent P-values <0.05.